Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
DentsplyXRAY |
$13M |
 |
Align TechnologyALGN |
-$137M |
 |
NovoCureNVCR |
-$124M |
 |
iRhythm TechnologiesIRTC |
-$608M |
 |
LeMaitre VascularLMAT |
-$3.96B |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Noznesky Justin J | Nov 26, 2025 | Sell | 5,166 | $37.29 | $190,000 |
| WEHRWEIN SVEN | Nov 25, 2025 | Sell | 4,967 | $38 | $190,000 |
| WEHRWEIN SVEN | Nov 24, 2025 | Sell | 5,033 | $37.32 | $190,000 |
| Yuen Maggie | Nov 21, 2025 | Sell | 3,000 | $35.72 | $110,000 |
| Noznesky Justin J | Sep 12, 2025 | Sell | 3,000 | $36.3 | $110,000 |
| WEHRWEIN SVEN | Aug 22, 2025 | Sell | 5,000 | $37 | $190,000 |
| WEHRWEIN SVEN | Aug 19, 2025 | Sell | 5,000 | $36 | $180,000 |
| GROVES REGINA E | Aug 6, 2025 | Sell | 2,452 | $36.82 | $90,000 |
| Doraiswamy Vinayak | Aug 5, 2025 | Sell | 2,500 | $36.58 | $91,000 |
| Doraiswamy Vinayak | May 28, 2025 | Sell | 2,500 | $33.44 | $84,000 |
| Prange Karen | Mar 5, 2025 | Sell | 6,100 | $38.12 | $230,000 |
| Yuen Maggie | Aug 15, 2024 | Sell | 3,500 | $24.07 | $84,000 |
| Privitera Salvatore | May 30, 2024 | Buy | 5,000 | $22.25 | $110,000 |
| Noznesky Justin J | May 1, 2024 | Sell | 1,500 | $24.09 | $36,000 |
| Noznesky Justin J | Apr 1, 2024 | Sell | 1,500 | $30.39 | $46,000 |
| Dahlquist Karl S. | Mar 18, 2024 | Sell | 1,885 | $32.16 | $61,000 |
| Noznesky Justin J | Mar 12, 2024 | Sell | 1,500 | $36.72 | $55,000 |
| Dahlquist Karl S. | Mar 5, 2024 | Sell | 8,231 | $37.36 | $310,000 |
FAQ - Insider Transactions
The most recent insider transaction for Atricure was conducted by Noznesky Justin J, who sold 5,166 shares on November 26, 2025 at a price of $37.29 per share.
Privitera Salvatore has bought the most ATRC stock in the last 2 years, with a total value of $110,000.
WEHRWEIN SVEN has sold the most ATRC stock in the last 2 years, with a total value of $740,000.
The total value of insider transactions for Atricure in the last 2 years is negative, amounting to -$2.1M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
Over the last 2 years, insider transactions for Atricure have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
